Atria Investments Inc Makes New $96,000 Investment in Intellia Therapeutics, Inc. $NTLA

Atria Investments Inc bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 10,217 shares of the company’s stock, valued at approximately $96,000.

Other large investors have also recently modified their holdings of the company. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 3.8% during the first quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after buying an additional 474,629 shares during the period. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock worth $76,447,000 after acquiring an additional 561,978 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Intellia Therapeutics by 8.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after acquiring an additional 38,521 shares during the period. Jump Financial LLC raised its position in shares of Intellia Therapeutics by 38.9% in the 1st quarter. Jump Financial LLC now owns 503,809 shares of the company’s stock worth $3,582,000 after acquiring an additional 141,172 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 55.3% in the 1st quarter. Granahan Investment Management LLC now owns 475,946 shares of the company’s stock valued at $3,384,000 after purchasing an additional 169,436 shares during the period. Institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several recent research reports. Citizens Jmp reduced their price target on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Jones Trading downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Bank of America lowered their price target on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Sanford C. Bernstein set a $14.50 price objective on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Finally, Robert W. Baird set a $9.00 target price on shares of Intellia Therapeutics in a research note on Thursday, October 30th. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $18.25.

Intellia Therapeutics Trading Up 0.3%

Intellia Therapeutics stock opened at $8.70 on Friday. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a fifty day simple moving average of $16.96 and a two-hundred day simple moving average of $12.51. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -2.04 and a beta of 2.44.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. During the same period last year, the firm posted ($1.34) earnings per share. Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Activity

In other news, CAO Michael P. Dube sold 1,871 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William J. Chase purchased 100,000 shares of Intellia Therapeutics stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director directly owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.10% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.